Development of novel viral vectored vaccines against Marburgviruses inducing robust and cross-reactive protection

Project Information

MARVAX

Grant agreement ID: 101137183

DOI

10.3030/101137183

EC signature date 23 November 2023

Start date 1 December 2023

End date 30 November 2027

Funded under

• Health

Total cost

€ 7 439 560,00

EU contribution

€ 7 439 560,00

Coordinated by

BERNHARD-NOCHT-INSTITUT FUER TROPENMEDIZIN
Germany

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Deliverables

Documents, reports (3)

Ethics Advisory Board

Composition of the Ethics Advisory Board (members selected and approved)

Ethics Advisory Board report (first period)

Report by the Ethics Advisory Board concerning ethical standard compliance of MARVAX during first reporting period.

Scientific and Innovation Advisory Board

Composition of the Scientific and Innovation Advisory Board (members selected and approved)

Websites, patent fillings, videos etc. (1)

Website

Website is live online.

Publications

Peer reviewed articles (1)

MVA-based vaccine candidates expressing SARS-CoV-2 prefusion-stabilized spike proteins of the Wuhan, Beta or Omicron BA.1 variants protect transgenic K18-hACE2 mice against Omicron infection and elicit robust and broad specific humoral and cellular immune responses

Author(s): Patricia Pérez; Patricia Pérez; David Astorgano; Guillermo Albericio; Sara Flores; Cristina Sánchez-Corzo; María A. Noriega; Pedro J. Sánchez-Cordón; Nuria Labiod; Nuria Labiod; Rafael Delgado; Rafael Delgado; Rafael Delgado; José M. Casasnovas; Mariano Esteban; Juan García-Arriaza; Juan García-Arriaza
Published in: Frontiers in Immunology, Issue 15, 2024, ISSN 1664-3224
Publisher: Lausanne: Frontiers Media S.A.
DOI: 10.3389/FIMMU.2024.1420304